Late-breaking presentation at SID and featured presentation at the ATS Respiratory Innovation Summit highlight KT-621 BroADen Phase 1b clinical ...

Autoimmune bullous disorders constitute a group of rare but potentially life‐threatening dermatological conditions marked by the production of pathogenic autoantibodies directed against structural ...

The DWP has confirmed the full list of 24 skin conditions that could make someone eligible for PIP weekly payments. Here are ...

PIP consists of 'daily living' and 'mobility'components Claimants may qualify for one, both, or neither, subject to their assessment ...

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late ...

Regeneron Pharmaceuticals, Inc. ( REGN) Bank of America Global Healthcare Conference 2026 May 12, 2026 1:00 PM EDT ...

First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent- global net sales (recorded by Sanofi) increased 33% to $4.9 billion EYLEA HD- U.S. net sales increased 52% ...

This information explains what bullous pemphigoid is and how to treat it. Bullous pemphigoid (BUL-us PEM-fih-goid) is a rare skin condition. It causes large fluid-filled blisters to form on your skin.

Clinical review: Bullous pemphigoid Contributed by Dr James Powell, specialist registrar in dermatology, Solihull Hospital, Birmingham.

Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Its pathogenesis involves the disruption of the basement membrane zone (BMZ), driven by pathogenic ...

A 58-year-old male patient presented to the dermatology clinic at West China Hospital of Sichuan University (Chengdu, Sichuan Province, China) in July, 2023, with vesicles, bullae, and erythematous ...